Abstracts tagged "Takayasu.s arteritis"

Abstract Number: 0161 • ACR Convergence 2021
Does 18F-FDG-PET/MRI Add Metabolic Information to Anatomic Image in Childhood-onset Takayasu’s Arteritis Patients? A Multicenter Case Series
Gleice Clemente¹, Alexandre Souza², Hilton Leão Filho³, Fernando Coelho³, Carlos Buchpiguel⁴, Marcos Lima⁴, Daniela Petry Pioto⁵, Melissa Fraga¹, Ana Paula Sakamoto⁶, Camila Carneiro⁴, Rosa Pereira⁷, Nadia Aikawa⁷, Clovis Artur Silva⁷, Lucia Campos⁸, Camilla Astley⁹, Bruno Gualano¹⁰ and Maria Terreri¹¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP-EPM, São Paulo, Brazil, ³Universidade de Sao Paulo/Radiology Institute, São Paulo, Brazil, ⁴Universidade de São Paulo/Department of Radiology and Oncology, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁶Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ⁷Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸children's institute, Sao Paulo, Brazil, ⁹University of Sao Paulo, Sao Paulo, Brazil, ¹⁰Universidade de Sao Paulo/Rheumatology Division, São Paulo, Brazil, ¹¹UNIFESP, São Paulo, Brazil
Background/Purpose: The disease activity assessment in c-TA is a challenge in clinical practice, especially in patients who are under immunosuppression. Our aim was to perform…
Abstract Number: 0503 • ACR Convergence 2021
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Kaitlin Quinn¹, Mark A. Ahlman², Hugh Alessi³, Ashkan Malayeri², Jamie Marko², Elaine Novakovich² and Peter Grayson⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
Abstract Number: 1194 • ACR Convergence 2021
A Module on Large Vessel Vasculitis for Learners in Rheumatology
David Shoemaker¹, Stamatina Danielides¹, Abhishek Nandan¹, Huzaefah Syed², Beth Rubinstein¹ and Seema Patel¹, ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Of the rheumatic disorders that learners are expected to know, the vasculitides are among the hardest to grasp. Their pathogenesis is not well-established, they…
Abstract Number: 1728 • ACR Convergence 2021
Takayasu’s Arteritis and Pregnancy: A Meta-analysis
Aine Gorman¹, Leah Rooney², Matthew Turk¹, Louise Moore³, Jared Bierbrier⁴, Celine O'Brien⁵, Anne Clohessy⁶, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala McAuliffe⁹ and Douglas Veale¹⁰, ¹St Vincents Hospital, Dublin, Ireland, ²St Vincent's University Hospital, Dublin, Ireland, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁴McMaster University, Hamilton, ON, Canada, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶National Maternity Hopistal, Dublin, Ireland, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹National Maternity Hopsital Dublin, Dublin, Ireland, ¹⁰University College Dublin, Dublin, Ireland
Background/Purpose: Takayasu’s arteritis is a systemic autoimmune disease characterised by large vessel vasculitis. It usually affects women of childbearing age, with 90% of patients diagnosed…
Abstract Number: 1862 • ACR Convergence 2021
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Kristina Wells¹, Fernanda Gutierrez-Rodrigues², Bhavisha Patel², Kaitlin Quinn³, Keith Sikora¹, Neal Young⁴ and Peter Grayson⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institues of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…
Abstract Number: 1864 • ACR Convergence 2021
18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis
Ertugrul Cagri bolek¹, Kaitlin Quinn², Hugh Alessi³, Elaine Novakovich⁴, Mark A. Ahlman⁴ and Peter Grayson⁵, ¹Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Imaging modalities play an important role in the diagnosis and management of patients with large-vessel vasculitis (LVV). Use of 18F-fluorodeoxyglucose (FDG) positron emission tomography…
Abstract Number: 1867 • ACR Convergence 2021
Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis
Andrew Porter¹, Robert Maughan¹, Charis Pericleous¹, Allan Kiprianos¹, Hyuk Jee², Pui Lee², Taryn Youngstein¹ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Boston Children's Hospital, Newton, MA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) leads to a broad phenotype that in some resembles polyarteritis nodosa with fever and rash, but in others…
Abstract Number: 1874 • ACR Convergence 2021
Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
Kaitlin Quinn¹, Hugh Alessi², Emily Rose³, Mark A. Ahlman⁴, Christopher Redmond⁴, Yiming Luo⁴, Ertugrul Cagri bolek⁵, Carol Langford⁶, Cristina Ponte⁷, Peter Merkel⁸ and Peter Grayson⁹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, Maryland, ³Case Western, Cleveland Heights, OH, ⁴National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷Hospital de Santa Maria, Lisbon, Portugal, ⁸University of Pennsylvania, Philadelphia, PA, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity assessment can be challenging in Takayasu’s arteritis (TAK), which can lead to difficulty in determining eligibility for enrollment into randomized clinical trials…
Abstract Number: 1877 • ACR Convergence 2021
Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics
Yiming Luo¹, Kaitlin Quinn², Marcela Ferrada¹, Elaine Novakovich¹ and Peter Grayson³, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Takayasu’s arteritis (TAK) is an idiopathic inflammatory disease primarily affecting the aorta and its major branches. Mycobacterium tuberculosis is prevalent in developing countries and…
Abstract Number: 1878 • ACR Convergence 2021
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Diana Prieto-Peña¹, Pilar Bernabeu², Paloma Vela³, Javier Narvaez⁴, Jesús Carlos Fernández-López⁵, Mercedes Freire⁶, Beatriz González-Alvarez⁷, Roser Solans-Laqué⁸, José Luis Callejas⁹, Norberto Ortego¹⁰, Carlos Fernández-Díaz¹¹, Esteban Rubio Romero¹², Salvador Garcia-Morillo¹³, Mauricio Minguez¹⁴, Cristina Carballido¹⁴, Eugenio De Miguel¹⁵, Sheila Melchor¹⁶, Eva Salgado¹⁷, Beatriz Bravo¹⁸, Susana Romero-Yuste¹⁹, Juan Salvatierra²⁰, Cristina Hidalgo²¹, Sara Manrique Arija²², Carlos Romero Gomez²³, Patricia Moya²⁴, Noelia Álvarez-Rivas²⁵, Javier Mendizábal-Mateos²⁶, Francisco Ortiz-Sanjuán²⁷, Ivan Perez De Pedro²⁸, Jose L Alonso-Valdivielso²⁹, Laura Perez-Sanchez³⁰, Rosa Roldan³¹, Nagore Fernandez-Llanio³², Ricardo Gómez de la Torre³³, Silvia Suarez³³, Mara Jess Montesa Cabrera³⁴, MONICA DELGADO SANCHEZ³⁵, Javier Loricera¹, Belén Atienza-Mateo³⁶, Miguel Ángel gonzalez-Gay³⁷ and Ricardo Blanco³⁸, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ³Hospital General Universitario de Alicante, Alicante, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ⁶Rheumatology Service. CHU Coruña, La Coruña, Spain, ⁷H. NªSª de la Candelaria, Tenerife, Spain, ⁸Hospital Vall d'Hebron, Barcelona, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Medicine Department, Universidad de Granada, Granada, Spain, ¹¹Hospital Universitario Reina Sofía, Murcia, Spain, ¹²HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, Seville, Spain, ¹³H Virgen del Rocio, Sevilla, Spain, ¹⁴H. San Juan, Alicante, Spain, ¹⁵Hospital Universitario La Paz, Madrid, Spain, ¹⁶H. 12 de Octubre, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ²⁰H San Juan, Alicante, Spain, ²¹Hospital Universitario Salamanca, Salamanca, Spain, ²²Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ²³H. Regional de Malaga, Malaga, Spain, ²⁴Hospital Sant Pau, Barcelona, Spain, ²⁵Hospital San Agustín, Aviles, Spain, ²⁶H. Navarra, Navarra, Spain, ²⁷H. La Fe, Valencia, Spain, ²⁸H. Carlos Haya, Malaga, Spain, ²⁹H. Burgos, Burgos, Spain, ³⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³¹H. Reina Sofia, Cordoba, Spain, ³²H. Arnau de Vilanova, Valencia, Spain, ³³H. Asturias, Oviedo, Spain, ³⁴Hospital Universitario Nuestra Seora de la Candelaria, Santa Cruz de Tenerife, Spain, ³⁵H NªSª Candelaria, Tenerife, Spain, ³⁶Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients.…
Abstract Number: 1882 • ACR Convergence 2021
Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
Tannaz Kermani¹, Jason Springer², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of California Los Angeles, Los Angeles, CA, ²Vanderbilt University Medical Center, Franklin, TN, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Health Informatics Institute, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: To compare the clinical characteristics and determine the reliability of a self-reported diagnosis of giant cell arteritis (GCA) or Takayasu’s arteritis (TAK) from an…
Abstract Number: 1886 • ACR Convergence 2021
Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis
K. Bates Gribbons¹, SEMA KAYMAZ-TAHRA², Fatma Alibaz³, Ertugrul Cagri bolek⁴, Omer Karadag⁵, Burak Ince⁶, Murat Inanc⁷, Sinem Kocaer⁸, Fatos Onen⁹, KENAN AKSU¹⁰, Gokhan Keser¹¹, Askin Ates¹², Ayten Yazici¹³, Ayse Cefle¹³, Nilufer Alpay Kanitez¹⁴, Ahmet Omma¹⁵, Onay Gercik¹⁶, Servet Akar¹⁷, Veli Cobankara¹⁸, Nazife Sule Yasar Bilge¹⁹, Timucin Kasifoglu²⁰, Mete Kara¹¹, Kaitlin Quinn²¹, Peter Grayson²², Peter Merkel²³ and Haner Direskeneli²⁴, ¹McGovern Medical School, Colleyville, TX, ²Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ⁸Dokuz Eylul University, Izmer, Turkey, ⁹Dokuz Eylul University, Izmir, Turkey, ¹⁰EGE UNIV. FACULTY of MEDICINE, IZMIR, Turkey, ¹¹Ege University, İzmir, Turkey, ¹²Ankara University, Ankara, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Koc University School of Medicine, Istanbul, Turkey, ¹⁵Ankara City Hospital, Istanbul, Turkey, ¹⁶Izmir Katip Celebi University, Izmir, Turkey, ¹⁷Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹⁸Pamukkale University, Denizli, Turkey, ¹⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ²⁰Osmangazi University Department of Rheumatology, Eskişehir, Turkey, ²¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Marmara University, Istanbul, Turkey
Background/Purpose: Previous studies using computer-driven methods have identified subsets of patients with Takayasu’s arteritis based on angiographic patterns of disease. These subsets were consistent between…
Abstract Number: 1692 • ACR Convergence 2020
Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
Camilla Astley¹, Saulo Gil², Gleice Clemente³, Maria Teresa Terreri⁴, Lucia Campos⁵, Nadia Aikawa⁵, Ana Lucia de-Sá Pinto², Rosa Pereira⁵, Hamilton Roschel² and Bruno Gualano², ¹University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, Sao paulo, Brazil, ³Federal University of Sao Paulo, Sao Paulo, Brazil, ⁴Federal University of São Paulo, São Paulo, Brazil, ⁵Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare, granulomatous, chronic large-vessel vasculitis that involves mostly the aorta and its major branches with a high mortality…
Abstract Number: 1922 • ACR Convergence 2020
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
K. Bates Gribbons¹, Kaitlin Quinn², Mark Ahlman³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹McGovern Medical School UT Houston, Houston, TX, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…
Abstract Number: 1923 • ACR Convergence 2020
Angiographic Progression of Disease in Large-Vessel Vasculitis
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Angiography is essential to detect vascular disease in patients with large-vessel vasculitis (LVV). Guidelines differ on the role of periodic angiography to monitor patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.